Azala

Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan

Background The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on healthy subjects up to 60 years. Methods The trial involved 150 subjects in randomized 2:1 groups...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Egile Nagusiak:	Gulbanu Sarsenbayeva (Egilea), Timur Issagulov (Egilea), Markhabat Kassenov (Egilea), Ruslan Abitay (Egilea), Mukhit Orynbayev (Egilea), Marina Stukova (Egilea), Maria Pisareva (Egilea), Timur Davlyatshin (Egilea), Kutumbetov Lespek (Egilea), Berik Khairullin (Egilea)
Formatua:	Liburua
Argitaratua:	Taylor & Francis Group, 2020-08-01T00:00:00Z.
Gaiak:	article
Sarrera elektronikoa:	Connect to this object online.
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults
nork: Gulbanu Sarsenbayeva, et al.
Argitaratua: (2018)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
nork: Ainur Nurpeisova, et al.
Argitaratua: (2022)

Immunogenicity and safety of a trivalent inactivated influenza vaccine
nork: Eddy Fadlyana, et al.
Argitaratua: (2011)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
nork: Zhaojun Mo, et al.
Argitaratua: (2017)

Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants
nork: Shelina Moonsamy, et al.
Argitaratua: (2019)

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis
nork: Sandrine I. Samson, et al.
Argitaratua: (2019)

Post-COVID syndrome and type 2 diabetes mellitus in Kazakhstan: clinical manifestations and vaccine efficacy
nork: Saule Altynbekova, et al.
Argitaratua: (2024)

Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults
nork: Ahmed Tawfik, et al.
Argitaratua: (2023)

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults
nork: Goran Stevanovic, et al.
Argitaratua: (2018)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
nork: Suvanna Asavapiriyanont, et al.
Argitaratua: (2018)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
nork: Yuemei Hu, et al.
Argitaratua: (2019)

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults
nork: Goran Stevanovic, et al.
Argitaratua: (2020)

Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore
nork: Yuk-Fai Lau, et al.
Argitaratua: (2017)

Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
nork: Yan Li, et al.
Argitaratua: (2021)

Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy
nork: Kei Nakashima, et al.
Argitaratua: (2017)

Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults
nork: Joon Young Song, et al.
Argitaratua: (2019)

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China
nork: Shi-Yuan Wang, et al.
Argitaratua: (2017)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
nork: Pablo Manuel Bianculli, et al.
Argitaratua: (2022)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
nork: Francesco Saverio Mennini, et al.
Argitaratua: (2018)

A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam
nork: Phan Trong Lan, et al.
Argitaratua: (2019)

Industrial traumatism and occupational morbidity in mining industry of Kazakhstan
nork: Nurbek Yerdessov, et al.
Argitaratua: (2021)

Efficacy of inactivated trivalent influenza vaccine in rural India: a 3-year cluster-randomised controlled trial
nork: Wayne M Sullender, ProfMD, et al.
Argitaratua: (2019)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
nork: Antonio Arbo, et al.
Argitaratua: (2022)

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
nork: Guillermo M. Ruiz-Palacios, et al.
Argitaratua: (2020)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
nork: Xiaoqiang Liu, et al.
Argitaratua: (2022)

Population-based screening leads to improved glaucoma diagnosis in Kazakhstan
nork: Lyaylya Bolatovna Tashtitova, et al.
Argitaratua: (2023)

Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice
nork: Aqian Li, et al.
Argitaratua: (2022)

Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms
nork: Yan Zhou, et al.
Argitaratua: (2023)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
nork: Juan Li, et al.
Argitaratua: (2021)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
nork: A.N. Mironov, et al.
Argitaratua: (2010)

How to Increase the Immunogenicity of SARS-COV-2 Inactivated Vaccines?
nork: Yousef Khadivi
Argitaratua: (2021)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
nork: A.N. Mironov, et al.
Argitaratua: (2010)

Clinical and economic efficiency of multi-matrix mesalazine in ulcerative colitis treatment in the healthcare system of the Republic of Kazakhstan
nork: Alima Almadiyeva, et al.
Argitaratua: (2019)

The effects of COVID-19 severity on health status in Kazakhstan: A prospective cohort study
nork: Elmira Kaidar, et al.
Argitaratua: (2024)

Air Pollution in Kazakhstan and Its Health Risk Assessment
nork: D. Kenessary, et al.
Argitaratua: (2019)

Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine.
nork: Shi-Hsia Hwa, et al.
Argitaratua: (2013)

Conceptualising the Integration of Action Research into the Practice of Teacher Education Universities in Kazakhstan
nork: Aiman Berikkhanova, et al.
Argitaratua: (2023)

IMMUNOGENICITY AND SAFETY OF A TRIVALENT SUBUNIT IMMUNOADJUVANT INFLUENZA VACCINE IN CHILDREN WITH TYPE 1 DIABETES: RESULTS OF A PROSPECTIVE COMPARATIVE STUDY
nork: Аlla A. Tarasova, et al.
Argitaratua: (2016)

First steps in forecasting the health workforce in Kazakhstan: A baseline scenario
nork: Berik Koichubekov, et al.
Argitaratua: (2021)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
nork: Shuyu Gao, et al.
Argitaratua: (2022)